Comparing the current results to its competitors, Agenus Inc reported Revenue increase in the 2 quarter 2026 by 34.36 % year on year. The sales growth was above Agenus Inc's competitors' average revenue growth of 10.15 %, achieved in the same quarter.
Agenus Inc's Comment on Competition and Industry Peers
The company faces competition from other drug candidates and approved drugs that may affect demand and pricing for its product candidates. Physicians may be hesitant to switch from existing treatments or may prefer other new drugs or biologics. The company depends on a limited number of suppliers for components required in clinical trials and commercial sales, and any disruptions could negatively impact operations. Manufacturing capacity is confined to a few cGMP-compliant manufacturers, which may influence profit margins and commercialization timelines. The company relies on third parties for development and commercialization activities; these partners may also collaborate with competitors, potentially affecting the company's performance. Intellectual property risks include challenges to patents, limited patent scope, and the possibility that competitors may develop similar or alternative technologies. Patent protection may be insufficient in duration or scope, exposing the company to competition from biosimilar or generic products.
September 9, 2025
Accessing Hope: France Provides Compassionate Use for Agenus BOT/BAL Therapy in Colorectal CancerIn a groundbreaking development for cancer treatment, Agenus Inc. has announced that its innovative BOT/BAL combination therapy featuring botensilimab and balstilimab is now available to eligible patients in France suffering from refractory metastatic colorectal cancer (MCC) that is stable at microsatellite status (MSS). This announcement marks a significant milestone in immuno-oncology, providing much-needed hope to patients who have exhausted other treatment options.The French National Agency for the Safety of Medicines and Health Products (ANSM) has formally granted this compassionate access, commonly referr...
April 26, 2025
In a notable stride toward innovating cancer care, Agenus Inc. (Nasdaq: AGEN), a leading company in the immuno-oncology landscape, has showcased compelling data from its ongoing Phase 1 study focusing on botensilimab (BOT) and balstilimab (BAL) in treating pretreated hepatocellular carcinoma (HCC). These findings were presented at the prestigious American Association for Cancer Research (AACR) Annual Meeting held recently in Chicago, Illinois, underscoring the potential transformative impact of these therapies in managing one of the most challenging forms of cancer. The Clinical Imperative in Hepatocellular CarcinomaHCC, the most prevalent form of primary liver cancer, often emerges in patients with underlyi...
April 23, 2025
In a world increasingly defined by its battle against cancer, innovations on the horizon remain a beacon of hope. Agenus Inc. (Nasdaq: AGEN), a trailblazer in the arena of immuno-oncology, is set to illuminate this field with three pivotal presentations at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting, scheduled for May 30 to June 3 in Chicago, Illinois. The spotlight will be on the promising therapies botensilimab and balstilimab, collectively known as the BOTBAL program, as the company unveils new translational data elucidating T-cell dynamics in mismatch repair proficient (pMMR) microsatellite stable (MSS) metastatic colorectal cancer.For those unfamiliar, immuno-oncology represents...
February 25, 2025
Agenus Inc. a biopharmaceutical company focused on immuno-oncology, is at the forefront of innovation aimed at improving treatment responses for colorectal cancer. The Lexington, Massachusetts-based company recently announced its p...
November 12, 2024
Innovations Amidst Challenges: Agenus Inc. Reports on Strategic Advancements in Cancer Immunotherapy In an era where the fight against cancer has prompted remarkable advancements, Agenus Inc. (Nasdaq: AGEN) stands out with its latest developments in immuno-oncology. On the heels of its third-quarter financial results for 2024, the company is not only reformulating its strategic efforts but also shedding light on significant progress in its pipeline, particularly concerning its lead program, BOT/BAL, which has shown promise as a treatment for microsatellite-stable (MSS) colorectal cancer. Transformative Potential of BOT/BAL The focal point of Agenus Inc. s recent corporate update is its BOT/BAL development. ...
September 30, 2024
The biotechnology sector continues to experience volatility, and particularly in the case of Agenus Inc. (NASDAQ: AGEN), financial hardship has prompted significant concerns among investors. Recent reports have highlighted that the company s cumulative net loss reached a staggering $283 million as of the third quarter of 2023. This has resulted in a troubling negative return on assets (ROA) of -73.23%, a metric that underlines the organization s challenges in leveraging its assets effectively to generate profits.In contrast, the broader Healthcare sector boasts 782 companies that recorded higher returns on assets during the same period. This disparity in performance raises inherent questions about the financ...
June 27, 2024
Botensilimab: A Defining Force in the Future of Cancer Treatment Cancer therapy has always been at the forefront of medical research and development, aiming to unlock new possibilities that offer hope to millions facing this debilitating disease. Recently, a promising development has emerged on the horizon, capturing the attention of the medical community and investors alike. The Cancer Therapy Evaluation Program (CTEP) has announced the availability of botensilimab for clinical studies, marking a significant milestone in the journey toward innovative cancer treatments. Emergence of Botensilimab: A Collaborative Effort CTEP, renowned for its dedication to advancing cancer treatments, is accepting Letters of...
May 23, 2024
Breakthrough Data on Botensilimab/Balstilimab in MSS CRC to be Presented at ASCO 2024 Agenus Inc. (Nasdaq: AGEN), a recognized leader in the development of innovative immunological therapies to combat cancer, has announced compelling new data surrounding their pioneering treatment involving botensilimab and balstilimab. This evidence is set to be unveiled at the esteemed American Society of Clinical Oncology (ASCO) Annual Meeting on June 1, 2024. The data arises from a Phase 1b trial focusing on patients with relapsed/refractory microsatellite stable colorectal cancer (r/r MSS CRC) who do not have active liver metastases (NLM). This patient subset often presents a daunting challenge for oncologists due to th...
Adaptimmune Therapeutics Plc is a biopharmaceutical company that focuses on developing and commercializing innovative cancer immunotherapy products. Their business model revolves around leveraging their T-cell receptor platform to engineer and develop targeted immunotherapies for patients with various types of cancer.
Fate Therapeutics Inc's business model revolves around the development and commercialization of innovative cell-based therapies to treat various diseases.
Inovio Pharmaceuticals Inc is a biotechnology company that focuses on the development and commercialization of immunotherapies for the treatment of various diseases, including cancers and infectious diseases. Their business model involves leveraging their proprietary platforms, such as DNA-based technology and electroporation, to design and develop novel vaccines and therapies which are then advanced through clinical trials and potential partnerships for further commercialization.
Intensity Therapeutics Inc's business model involves developing and commercializing novel intratumoral cancer immunotherapy products. They aim to target and destroy tumors within the body through the direct application of their proprietary drug, leading to an enhanced immune response and potential treatment for various cancers.
Iovance Biotherapeutics Inc operates on a business model centered around developing and commercializing novel cancer immunotherapy treatments. The company focuses on utilizing its proprietary Tumor Infiltrating Lymphocyte (TIL) therapy, which involves collecting and expanding a patient's own immune cells to target and kill cancer cells. Iovance primarily seeks to advance its TIL therapy candidates through clinical trials and collaborations while aiming to provide effective and personalized treatment options for cancer patients.
Sources:
Agenus Inc’s official press releases and regulatory filings; CSIMarket.com’s market research; and the financial filings and press releases of other companies cited in this report.
Updated on:
Focus of this report: publicly traded companies.
For your research, we’ve provided 10 tables on Agenus Inc versus competitors, including market share analysis.
You can find them in the navigation menu under Competition.
To download the tables, please subscribe.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.
